Targeting cyclin D1 as a therapeutic approach for papillary thyroid carcinoma

被引:4
作者
Cai, Wei [1 ]
Shu, Lin-Zhen [2 ]
Liu, Ding-Jie [3 ]
Zhou, Lv [1 ]
Wang, Meng-Meng [1 ]
Deng, Huan [1 ]
机构
[1] Nanchang Univ, Affiliated Hosp 4, Dept Pathol, Nanchang, Peoples R China
[2] Nanchang Univ, Med Coll, Nanchang, Peoples R China
[3] Jinan Univ, Zhuhai Peoples Hosp, Zhuhai Intervent Med Ctr, Zhuhai Precis Med Ctr,Zhuhai Hosp, Zhuhai, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
基金
美国国家科学基金会;
关键词
cell cycle; cyclin D1; CCND1; papillary thyroid carcinoma; pathogenesis; RETINOBLASTOMA GENE-PRODUCT; 4/6 INHIBITOR PALBOCICLIB; CELL-CYCLE; TYROSINE KINASE; BREAST-CANCER; BETA-CATENIN; SIGNAL TRANSDUCER; BRAF MUTATIONS; NUCLEAR EXPORT; CDK INHIBITORS;
D O I
10.3389/fonc.2023.1145082
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cyclin D1 functions as a mitogenic sensor that specifically binds to CDK4/6, thereby integrating external mitogenic inputs and cell cycle progression. Cyclin D1 interacts with transcription factors and regulates various important cellular processes, including differentiation, proliferation, apoptosis, and DNA repair. Therefore, its dysregulation contributes to carcinogenesis. Cyclin D1 is highly expressed in papillary thyroid carcinoma (PTC). However, the particular cellular mechanisms through which abnormal cyclin D1 expression causes PTC are poorly understood. Unveiling the regulatory mechanisms of cyclin D1 and its function in PTC may help determine clinically effective strategies, and open up better opportunities for further research, leading to the development of novel PTC regimens that are clinically effective. This review explores the mechanisms underlying cyclin D1 overexpression in PTC. Furthermore, we discuss the role of cyclin D1 in PTC tumorigenesis via its interactions with other regulatory elements. Finally, recent progress in the development of therapeutic options targeting cyclin D1 in PTC is examined and summarized.
引用
收藏
页数:10
相关论文
共 144 条
  • [1] Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas
    Adeniran, AJ
    Zhu, ZW
    Gandhi, M
    Steward, DL
    Fidler, JP
    Giordano, TJ
    Biddinger, PW
    Nikiforov, YE
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2006, 30 (02) : 216 - 222
  • [2] Integrated Genomic Characterization of Papillary Thyroid Carcinoma
    Agrawal, Nishant
    Akbani, Rehan
    Aksoy, B. Arman
    Ally, Adrian
    Arachchi, Harindra
    Asa, Sylvia L.
    Auman, J. Todd
    Balasundaram, Miruna
    Balu, Saianand
    Baylin, Stephen B.
    Behera, Madhusmita
    Bernard, Brady
    Beroukhim, Rameen
    Bishop, Justin A.
    Black, Aaron D.
    Bodenheimer, Tom
    Boice, Lori
    Bootwalla, Moiz S.
    Bowen, Jay
    Bowlby, Reanne
    Bristow, Christopher A.
    Brookens, Robin
    Brooks, Denise
    Bryant, Robert
    Buda, Elizabeth
    Butterfield, Yaron S. N.
    Carling, Tobias
    Carlsen, Rebecca
    Carter, Scott L.
    Carty, Sally E.
    Chan, Timothy A.
    Chen, Amy Y.
    Cherniack, Andrew D.
    Cheung, Dorothy
    Chin, Lynda
    Cho, Juok
    Chu, Andy
    Chuah, Eric
    Cibulskis, Kristian
    Ciriello, Giovanni
    Clarke, Amanda
    Clayman, Gary L.
    Cope, Leslie
    Copland, John A.
    Covington, Kyle
    Danilova, Ludmila
    Davidsen, Tanja
    Demchok, John A.
    DiCara, Daniel
    Dhalla, Noreen
    [J]. CELL, 2014, 159 (03) : 676 - 690
  • [3] IKKα regulates mitogenic signaling through transcriptional induction of cyclin D1 via Tcf
    Albanese, C
    Wu, KM
    D'Amico, M
    Jarrett, C
    Joyce, D
    Hughes, J
    Hulit, J
    Sakamaki, T
    Fu, MF
    Ben-Ze'ev, A
    Bromberg, JF
    Lamberti, C
    Verma, U
    Gaynor, RB
    Byers, SW
    Pestell, RG
    [J]. MOLECULAR BIOLOGY OF THE CELL, 2003, 14 (02) : 585 - 599
  • [4] Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation
    Alt, JR
    Cleveland, JL
    Hannink, M
    Diehl, JA
    [J]. GENES & DEVELOPMENT, 2000, 14 (24) : 3102 - 3114
  • [5] Targeting Non-Oncogene Addiction: Focus on Thyroid Cancer
    Anania, Maria Chiara
    Di Marco, Tiziana
    Mazzoni, Mara
    Greco, Angela
    [J]. CANCERS, 2020, 12 (01)
  • [6] Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E
    Antonello, Zeus A.
    Hsu, Nancy
    Bhasin, Manoj
    Roti, Giovanni
    Joshi, Mukta
    Van Hummelen, Paul
    Ye, Emily
    Lo, Agnes S.
    Karumanchi, S. Ananth
    Bryke, Christine R.
    Nucera, Carmelo
    [J]. ONCOTARGET, 2017, 8 (49) : 84743 - 84760
  • [7] The history and future of targeting cyclin-dependent kinases in cancer therapy
    Asghar, Uzma
    Witkiewicz, Agnieszka K.
    Turner, Nicholas C.
    Knudsen, Erik S.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (02) : 130 - 146
  • [8] Consequence of the tumor-associated conversion to cyclin D1b
    Augello, Michael A.
    Berman-Booty, Lisa D.
    Carr, Richard
    Yoshida, Akihiro
    Dean, Jeffry L.
    Schiewer, Matthew J.
    Feng, Felix Y.
    Tomlins, Scott A.
    Gao, Erhe
    Koch, Walter J.
    Benovic, Jeffrey L.
    Diehl, John Alan
    Knudsen, Karen E.
    [J]. EMBO MOLECULAR MEDICINE, 2015, 7 (05) : 628 - 647
  • [9] Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1
    Averous, J.
    Fonseca, B. D.
    Proud, C. G.
    [J]. ONCOGENE, 2008, 27 (08) : 1106 - 1113
  • [10] Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells
    Balmanno, K
    Cook, SJ
    [J]. ONCOGENE, 1999, 18 (20) : 3085 - 3097